Precipio
Company Snapshot
Company Overview
Precipio Inc. is developing liquid biopsy-based diagnostics products and services for cancer applications. In October 2016 Precipio merged with Transgenomic and integrated the two companies’ operations.
Precipio uses BLOCker sequencing that increases the sensitivity for certain mutations. The firm also offers a mutation enrichment platform called ICE Cold-PCR (ICP), which can be combined with blocking oligonucleotides in cycle (BLOCker) sequencing to achieve very low detection limits on Sanger platforms.
In BLOCker sequencing, a locked nucleic acid (LNA) is inserted into the oligonucleotide. This blocks wild-type DNA to be sequenced at specific positions while permitting mutated DNA to be sequenced at the same position. During the Sanger sequencing cycle, the blocking oligo is added and anneals to the template. During the cycle, the temperature is increased, causing the oligo to separate from the mutated DNA, but remain annealed to the wild-type DNA. The oligo remains attached to the wild-type DNA, so it cannot be sequenced.
Precipio operates a CLIA laboratory in New Haven, Conn., and in 2017 launched a redesigned ICP target enrichment kit to identify mutations in lung cancer using liquid biopsies.
In May 2018 Precipio launched its ICP KRAS liquid biopsy kits for pancreatic cancer. The kits are available in both qPCR and Sanger sequencing platforms and use the ICP technology. The target market for these kits is as enrichment technology for laboratories developing screening and monitoring tests.
In November 2018 Precipio formed an alliance with PerkinElmer covering liquid biopsy test development and using Precipio’s ICP platform.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Precipio In News
Company's Business Segments
- Service : This segment includes Medicaid, Medicare, Self-pay, Third Party Payers, Contract Diagnostics and Others.
- Product : This segment includes Molecular Kits, MPN Panel, BCR-ABL1 Panel, ABL1 Resistance Panel, AML Panel, CLL Panel, Cytopenia Panel
Applications/End User Industries
- Hematopathology Services
- Bloodhound MPN
- HemeScreen Reagents
- Hospitals
- Healthcare